{"organizations": [], "uuid": "1912f5fad71636b811d0059725d94abb85eeeb5c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-aclaris-therapeutics-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2017-financial-results-on-march-12.html", "country": "US", "domain_rank": 767, "title": "Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T16:00:00.000+02:00", "replies_count": 0, "uuid": "1912f5fad71636b811d0059725d94abb85eeeb5c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-aclaris-therapeutics-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2017-financial-results-on-march-12.html", "ord_in_thread": 0, "title": "Aclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "pa.", "sentiment": "none"}, {"name": "wayne", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "aclaris therapeutics, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WAYNE, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, will report financial results for the fourth quarter and year ending December 31, 2017 on Monday, March 12, 2018, before the U.S. financial markets open.\nManagement will provide an update on the Company and discuss fourth quarter and year-end 2017 results as well as expectations for the future via conference call on Monday, March 12, 2018, at 8:00 AM ET. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 1495576 prior to the start of the call.\nA live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts . A replay of the webcast will be archived on the Aclaris website following the event.\nAbout Aclaris Therapeutics, Inc.\nAclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company is focused on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne, Pennsylvania and more information about the company can be found by visiting the Aclaris website at www.aclaristx.com .\nContact:\nAclaris Contact\nMichael Tung, M.D.\nSenior Vice President / Corporate Strategy / Investor Relations\n484-329-2140\nmtung@aclaristx.com\nMedia Contact\nLaura Morgan\nTogoRun\n347-342-8496\nL.Morgan@togorun.com\nSource:Aclaris Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=UPWMqFx_3YapnYahKgFi_LQqNik9_LE2htP6VH4hGbVol2axu_0_cLOPGRqXGjX-3Gzra5TqZQwyzdgHwjnEtHCO5wnAuiI7gmJyw7DUXtg9YWL_SBgvOewqG-qc0BN5nKUYYaJXhWoiRf7eAh2II2_6mxBvNN-vzeYk-4nRWT8iJudfaGe_BijLbsfa7H5lP6X7RosfRV-JCfc3J42nrcFywWqjZUkNBlvV95hGRGk=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/f070dd10-8174-4c0b-b7f6-dd7ec69540ae", "https://www.globenewswire.com/Tracker?data=Yn3YgBiVBDid1aWFDRXVUA853NgIJ8j3KmjxC6wVRumFhht12NYATqNrCuH7r6z0n6j_HxOwlBMoKCwTUpGuQ_4uadTc8QOJ8tz5F0V2DBvspX9R4fy-3IzO0s4zWF59_-EV8LE4I4q3oqZHZlr3dngbcFLSiXnnharEIAD5UVPGGPnPNLJrhVVEgWG1487Vm2o-znQi7fFtNQ5YuP8jJIu0oosMgizb9aqdSRa5I503M4CNxKwY3xZ2vTxISrD3Ng-q875EaTuTAOTihiDAR0aDThXd7k86bFPiPnUL-t0uR4QUiT0ms5TFM89CWDyEbOLnPgA7ePEH1EYvdKZhy-nFHKTujr0jBi3iC6iYwGBulDBeRJsd3tBWFCVDnXgpIgBreoYEbYcGR1MVAk7dubIcX-vl38AoqP1GJoPuxZ-MGQ3q9pS3FALZRxUFeXcxjrF0PzdqkooWTuSAGcU0ckI_jqsq5TZde3FXmOn", "http://www.aclaristx.com/events-and-webcasts", "https://www.globenewswire.com/Tracker?data=yxiAxSukPI31r7WjyKyCMeOGtQUXOugTBAh5RCL-uVsbuuVhzUWUO1V0o9G-A2Nqg9d-DjWhxe4eQaFyOA8G47hT5eVP1Mv6ORlQR8VNnkr77mhPIRTWHYI2EZkpt5b9LxhS49L4a-_BX6FKg2nG9l4sOQgDx4zxwAc_FfDkVN61QnLx6skjzw8BLib_BkccHp2iNCKbM21VZ8-ErUZlpQLBqP8n_z5xfiYmq6kAFgGFVC5wYgwDlPnTmfiWfYrMbDRVCcxcrPR3jetB6HBenw=="], "published": "2018-02-28T16:00:00.000+02:00", "crawled": "2018-02-28T17:50:58.015+02:00", "highlightTitle": ""}